$350m Adaptimmune deal shows GSK still does cancer R&D
This article was originally published in Scrip
GlaxoSmithKline, recently assumed by some industry commentators to be exiting oncology, has signed a deal with immunotherapy company Adaptimmune which could be worth more than $350m. The collaboration underlines GSK's stated ambition to pour major investment into immuno-oncology.
You may also be interested in...
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.